Middle East Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarker (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays), By End Use, By Region, And Segment Forecasts, 2025 - 2033
The Middle East renal biomarkers market size was estimated at USD 191.23 million in 2024 and is projected to reach USD 399.33 million by 2033, growing at a CAGR of 8.67% from 2025 to 2033. The burden of kidney disease is increasing steadily across the Middle East, driven by high rates of diabetes, hypertension, and obesity. Chronic kidney disease (CKD) and acute kidney injury (AKI) are emerging as major public health concerns, creating a growing need for earlier and more accurate detection methods beyond conventional testing. CKD often progresses silently until advanced stages, which makes biomarker-based diagnostics especially valuable for early intervention. In January 2025, Biomed Central highlighted a recent population-based study in the Kingdom of Saudi Arabia that reported an overall prevalence of chronic kidney disease (CKD) of 4.76% (95% CI: 4.72-4.80%) among adults tested between 2015 and 2022.
Reports from the International Society of Nephrology (ISN) Global Kidney Health Atlas in 2024, as well as other studies, highlight that the Middle East and North Africa (MENA) regions have a high prevalence of CKD risk factors, including diabetes, obesity, and hypertension. This high burden underscores the urgent need for more effective early diagnostic tools, including advanced renal biomarkers, to enhance patient outcomes. The International Society of Nephrology Global Kidney Health Atlas reports that in the Middle East region, the prevalence of CKD ranged from ~5.24% to ~10.57% among different countries. Further, for the end?stage kidney disease (ESKD) treated with renal replacement therapy in the Gulf region: one study in the GCC found a mean prevalence of ESKD of 551 per million population (pmp), with country?specific extremes such as Oman (~1000 pmp) and Qatar (~347 pmp).
In July 2025, Serum KIM-1 and Cystatin C levels were assessed as early biomarkers for kidney injury by a study that included participants from Middle East University (MEU) and Al-Yarmouk University. According to the snippet's source, another study examined the use of serum KIM-1 as an early diagnostic marker for diabetic nephropathy and found markedly elevated levels in diabetic groups. This study may have involved researchers or institutions from the Middle East. In addition to being a biomarker for acute kidney injury (AKI), studies have shown that KIM-1 serves as an entry point for several enveloped viruses, including the Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. Given the origin of MERS-CoV, this emphasizes a particular regional relevance for KIM-1 research.
The Middle East renal biomarkers industry is gradually moving toward advanced laboratory automation and precision diagnostic systems. Hospitals and reference labs in Saudi Arabia and the United Arab Emirates are adopting automated analyzers and multiplex immunoassays that enhance detection accuracy and reduce turnaround times. The integration of advanced chemistry analyzers, AI-based data interpretation, and cloud-linked laboratory information systems is allowing clinicians to identify kidney damage at earlier stages. International diagnostic companies are also expanding their regional partnerships, providing access to innovative biomarker panels, such as NGAL, KIM-1, and cystatin C, which help detect subclinical kidney injury before it becomes irreversible.
Saudi Arabia and the UAE are leading the region in healthcare infrastructure. Both countries have invested heavily in modern hospitals, laboratories, and digital health systems that enable advanced diagnostic testing. Kuwait closely follows with well-equipped tertiary hospitals and a growing network of diagnostic services. Oman and Qatar are enhancing their diagnostic infrastructure, but access to high-end testing remains limited outside major cities.
Middle East Renal Biomarkers Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East renal biomarkers market based on biomarker, diagnostic technique, end use, and region:
Reports from the International Society of Nephrology (ISN) Global Kidney Health Atlas in 2024, as well as other studies, highlight that the Middle East and North Africa (MENA) regions have a high prevalence of CKD risk factors, including diabetes, obesity, and hypertension. This high burden underscores the urgent need for more effective early diagnostic tools, including advanced renal biomarkers, to enhance patient outcomes. The International Society of Nephrology Global Kidney Health Atlas reports that in the Middle East region, the prevalence of CKD ranged from ~5.24% to ~10.57% among different countries. Further, for the end?stage kidney disease (ESKD) treated with renal replacement therapy in the Gulf region: one study in the GCC found a mean prevalence of ESKD of 551 per million population (pmp), with country?specific extremes such as Oman (~1000 pmp) and Qatar (~347 pmp).
In July 2025, Serum KIM-1 and Cystatin C levels were assessed as early biomarkers for kidney injury by a study that included participants from Middle East University (MEU) and Al-Yarmouk University. According to the snippet's source, another study examined the use of serum KIM-1 as an early diagnostic marker for diabetic nephropathy and found markedly elevated levels in diabetic groups. This study may have involved researchers or institutions from the Middle East. In addition to being a biomarker for acute kidney injury (AKI), studies have shown that KIM-1 serves as an entry point for several enveloped viruses, including the Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2. Given the origin of MERS-CoV, this emphasizes a particular regional relevance for KIM-1 research.
The Middle East renal biomarkers industry is gradually moving toward advanced laboratory automation and precision diagnostic systems. Hospitals and reference labs in Saudi Arabia and the United Arab Emirates are adopting automated analyzers and multiplex immunoassays that enhance detection accuracy and reduce turnaround times. The integration of advanced chemistry analyzers, AI-based data interpretation, and cloud-linked laboratory information systems is allowing clinicians to identify kidney damage at earlier stages. International diagnostic companies are also expanding their regional partnerships, providing access to innovative biomarker panels, such as NGAL, KIM-1, and cystatin C, which help detect subclinical kidney injury before it becomes irreversible.
Saudi Arabia and the UAE are leading the region in healthcare infrastructure. Both countries have invested heavily in modern hospitals, laboratories, and digital health systems that enable advanced diagnostic testing. Kuwait closely follows with well-equipped tertiary hospitals and a growing network of diagnostic services. Oman and Qatar are enhancing their diagnostic infrastructure, but access to high-end testing remains limited outside major cities.
Middle East Renal Biomarkers Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East renal biomarkers market based on biomarker, diagnostic technique, end use, and region:
- Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
- Functional Biomarkers
- Serum Creatinine
- Blood Urea Nitrogen (BUN)
- Estimated Glomerular Filtration Rate (eGFR)
- Upregulated Proteins
- Kidney Injury Molecule-1 (KIM-1)
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Cystatin C
- Interleukin-18 (IL-18)
- Others
- Other Novel Biomarkers
- microRNA biomarkers
- Proteomic/metabolomic markers
- Diagnostic Technique/Platform Outlook (Revenue, USD Million, 2021 - 2033)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunoassays
- Clinical Chemistry Assays
- Point-of-Care Testing (POCT) Devices
- Molecular Diagnostics
- Other Emerging Platforms
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- Middle East
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
CHAPTER 1. MIDDLE EAST RENAL BIOMARKERS MARKET: METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Biomarkers Segment
1.1.1.2. Diagnostic Technique/Platform Segment
1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective -
1.4.2. Objective -
1.4.3. Objective -
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
CHAPTER 2. MIDDLE EAST RENAL BIOMARKERS MARKET: EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. MIDDLE EAST RENAL BIOMARKERS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Rising prevalence of kidney diseases:
3.3.1.2. Government Initiatives and Health Awareness Programs
3.3.1.3. Technological advancements in kidney diagnostics
3.3.2. Market restraint analysis
3.3.2.1. High cost of diagnostic tests
3.3.2.2. Limited availability of trained personnel to perform and interpret biomarker tests
3.4. Middle East Renal Biomarker Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.2. PESTEL Analysis
CHAPTER 4. MIDDLE EAST RENAL BIOMARKERS MARKET: BIOMARKERS ESTIMATES & TREND ANALYSIS
4.1. Middle East Renal Biomarkers Market: Biomarkers Movement Analysis
4.2. Functional Biomarkers
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.2. Serum Creatinine
4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.3. Blood Urea Nitrogen (BUN)
4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.4. Estimated Glomerular Filtration Rate (eGFR)
4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Upregulated Proteins
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2. Kidney Injury Molecule-1 (KIM-1)
4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.3. Neutrophil Gelatinase-Associated Lipocalin (NGAL)
4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.4. Cystatin C
4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.5. Interleukin-18 (IL-18)
4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.6. Others
4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Other Novel Biomarkers
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. microRNA biomarkers
4.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Proteomic/metabolomic markers
4.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
CHAPTER 5. MIDDLE EAST RENAL BIOMARKERS MARKET: DIAGNOSTIC TECHNIQUE/PLATFORM ESTIMATES & TREND ANALYSIS
5.1. Middle East Renal Biomarkers Market: Diagnostic Technique/Platform Movement Analysis
5.2. Enzyme-Linked Immunosorbent Assay (ELISA)
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Molecular Diagnostics
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Immunoassays
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Clinical Chemistry Assays
5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Point-of-Care Testing (POCT) Devices
5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Other Emerging Platforms
5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
CHAPTER 6. MIDDLE EAST RENAL BIOMARKERS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Middle East Renal Biomarkers Market: End Use Movement Analysis
6.2. Hospitals and clinics
6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Diagnostics Laboratories
6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Academic & Research Institutes
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Pharmaceutical & Biotechnology Companies
6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
CHAPTER 7. MIDDLE EAST RENAL BIOMARKERS MARKET: REGIONAL BUSINESS ANALYSIS
7.1. Regional Market Snapshot
7.2. Middle East
7.2.1. Middle East Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.2. Saudi Arabia
7.2.2.1. Saudi Arabia Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. UAE
7.2.3.1. UAE Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.2.4. Kuwait
7.2.4.1. Kuwait Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.4.2. Key Country Dynamics
7.2.4.3. Regulatory Framework
7.2.4.4. Reimbursement Scenario
7.2.4.5. Competitive Scenario
7.2.5. Oman
7.2.5.1. Oman Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.5.2. Key Country Dynamics
7.2.5.3. Regulatory Framework
7.2.5.4. Reimbursement Scenario
7.2.5.5. Competitive Scenario
7.2.6. Qatar
7.2.6.1. Qatar Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.6.2. Key Country Dynamics
7.2.6.3. Regulatory Framework
7.2.6.4. Reimbursement Scenario
7.2.6.5. Competitive Scenario
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. NEW BIOMARKERS LAUNCH
8.2.2. PARTNERSHIPS
8.2.3. ACQUISITION
8.2.4. COLLABORATION
8.2.5. FUNDING
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. Thermo Fisher Scientific Inc.
8.5.2. Company Overview
8.5.2.1. Financial Performance
8.5.2.2. Biomarkers Benchmarking
8.5.2.3. Strategic Initiatives
8.5.3. Siemens Healthineers AG
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Biomarkers Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. BioPorto Diagnostics A/S
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Biomarkers Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. SEKISUI Medical Co., Ltd
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Biomarkers Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. BioMerieux SA
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Biomarkers Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. SphingoTec GmbH
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Biomarkers Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Randox Laboratories Ltd
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Biomarkers Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Beckman Coulter Inc.
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Biomarkers Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. QIAGEN N.V.
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Biomarkers Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. GENEX LAB
8.5.11.1. Company Overview
8.5.11.2. Financial Performance
8.5.11.3. Biomarkers Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. BIO PREVENTIVE MEDICINE
8.5.12.1. Company Overview
8.5.12.2. Financial Performance
8.5.12.3. Biomarkers Benchmarking
8.5.12.4. Strategic Initiatives
8.5.13. M42’S DIAVERUM
8.5.13.1. Company Overview
8.5.13.2. Financial Performance
8.5.13.3. Biomarkers Benchmarking
8.5.13.4. Strategic Initiatives
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Biomarkers Segment
1.1.1.2. Diagnostic Technique/Platform Segment
1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective -
1.4.2. Objective -
1.4.3. Objective -
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
CHAPTER 2. MIDDLE EAST RENAL BIOMARKERS MARKET: EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. MIDDLE EAST RENAL BIOMARKERS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Rising prevalence of kidney diseases:
3.3.1.2. Government Initiatives and Health Awareness Programs
3.3.1.3. Technological advancements in kidney diagnostics
3.3.2. Market restraint analysis
3.3.2.1. High cost of diagnostic tests
3.3.2.2. Limited availability of trained personnel to perform and interpret biomarker tests
3.4. Middle East Renal Biomarker Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.2. PESTEL Analysis
CHAPTER 4. MIDDLE EAST RENAL BIOMARKERS MARKET: BIOMARKERS ESTIMATES & TREND ANALYSIS
4.1. Middle East Renal Biomarkers Market: Biomarkers Movement Analysis
4.2. Functional Biomarkers
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.2. Serum Creatinine
4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.3. Blood Urea Nitrogen (BUN)
4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.4. Estimated Glomerular Filtration Rate (eGFR)
4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Upregulated Proteins
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2. Kidney Injury Molecule-1 (KIM-1)
4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.3. Neutrophil Gelatinase-Associated Lipocalin (NGAL)
4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.4. Cystatin C
4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.5. Interleukin-18 (IL-18)
4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.6. Others
4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Other Novel Biomarkers
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. microRNA biomarkers
4.4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Proteomic/metabolomic markers
4.4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
CHAPTER 5. MIDDLE EAST RENAL BIOMARKERS MARKET: DIAGNOSTIC TECHNIQUE/PLATFORM ESTIMATES & TREND ANALYSIS
5.1. Middle East Renal Biomarkers Market: Diagnostic Technique/Platform Movement Analysis
5.2. Enzyme-Linked Immunosorbent Assay (ELISA)
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Molecular Diagnostics
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Immunoassays
5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Clinical Chemistry Assays
5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Point-of-Care Testing (POCT) Devices
5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Other Emerging Platforms
5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
CHAPTER 6. MIDDLE EAST RENAL BIOMARKERS MARKET: END USE ESTIMATES & TREND ANALYSIS
6.1. Middle East Renal Biomarkers Market: End Use Movement Analysis
6.2. Hospitals and clinics
6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Diagnostics Laboratories
6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Academic & Research Institutes
6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Pharmaceutical & Biotechnology Companies
6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
CHAPTER 7. MIDDLE EAST RENAL BIOMARKERS MARKET: REGIONAL BUSINESS ANALYSIS
7.1. Regional Market Snapshot
7.2. Middle East
7.2.1. Middle East Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.2. Saudi Arabia
7.2.2.1. Saudi Arabia Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. UAE
7.2.3.1. UAE Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.2.4. Kuwait
7.2.4.1. Kuwait Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.4.2. Key Country Dynamics
7.2.4.3. Regulatory Framework
7.2.4.4. Reimbursement Scenario
7.2.4.5. Competitive Scenario
7.2.5. Oman
7.2.5.1. Oman Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.5.2. Key Country Dynamics
7.2.5.3. Regulatory Framework
7.2.5.4. Reimbursement Scenario
7.2.5.5. Competitive Scenario
7.2.6. Qatar
7.2.6.1. Qatar Renal Biomarkers Market, 2021 - 2033 (USD Million)
7.2.6.2. Key Country Dynamics
7.2.6.3. Regulatory Framework
7.2.6.4. Reimbursement Scenario
7.2.6.5. Competitive Scenario
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. NEW BIOMARKERS LAUNCH
8.2.2. PARTNERSHIPS
8.2.3. ACQUISITION
8.2.4. COLLABORATION
8.2.5. FUNDING
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. Thermo Fisher Scientific Inc.
8.5.2. Company Overview
8.5.2.1. Financial Performance
8.5.2.2. Biomarkers Benchmarking
8.5.2.3. Strategic Initiatives
8.5.3. Siemens Healthineers AG
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Biomarkers Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. BioPorto Diagnostics A/S
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Biomarkers Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. SEKISUI Medical Co., Ltd
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Biomarkers Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. BioMerieux SA
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Biomarkers Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. SphingoTec GmbH
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Biomarkers Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Randox Laboratories Ltd
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Biomarkers Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Beckman Coulter Inc.
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Biomarkers Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. QIAGEN N.V.
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Biomarkers Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. GENEX LAB
8.5.11.1. Company Overview
8.5.11.2. Financial Performance
8.5.11.3. Biomarkers Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. BIO PREVENTIVE MEDICINE
8.5.12.1. Company Overview
8.5.12.2. Financial Performance
8.5.12.3. Biomarkers Benchmarking
8.5.12.4. Strategic Initiatives
8.5.13. M42’S DIAVERUM
8.5.13.1. Company Overview
8.5.13.2. Financial Performance
8.5.13.3. Biomarkers Benchmarking
8.5.13.4. Strategic Initiatives
LIST OF TABLES
Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 Middle East Renal Biomarkers Market, By Region, 2021 - 2033 (USD Million)
Table 4 Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 5 Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 6 Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 7 Saudi Arabia Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 8 Saudi Arabia Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 9 Saudi Arabia Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 10 UAE Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 11 UAE Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 12 UAE Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 13 Kuwait Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 14 Kuwait Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 15 Kuwait Middle East Renal Biomarkers Market, By End Use, 32021 - 2033 (USD Million)
Table 16 Qatar Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 17 Qatar Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 18 Qatar Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 19 Oman Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 20 Oman Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 21 Oman Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 Middle East Renal Biomarkers Market, By Region, 2021 - 2033 (USD Million)
Table 4 Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 5 Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 6 Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 7 Saudi Arabia Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 8 Saudi Arabia Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 9 Saudi Arabia Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 10 UAE Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 11 UAE Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 12 UAE Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 13 Kuwait Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 14 Kuwait Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 15 Kuwait Middle East Renal Biomarkers Market, By End Use, 32021 - 2033 (USD Million)
Table 16 Qatar Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 17 Qatar Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 18 Qatar Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
Table 19 Oman Middle East Renal Biomarkers Market, By Biomarkers, 2021 - 2033 (USD Million)
Table 20 Oman Middle East Renal Biomarkers Market, By Diagnostic Technique/Platform, 2021 - 2033 (USD Million)
Table 21 Oman Middle East Renal Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Middle East renal biomarkers market- Key market driver analysis
Fig. 7 Middle East renal biomarkers market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Middle East renal biomarkers market - Porter’s analysis
Fig. 10 Middle East renal biomarkers market - PESTEL analysis
Fig. 11 Middle East renal biomarkers market Biomarkers outlook key takeaways
Fig. 12 Middle East renal biomarkers market: Biomarkers movement analysis
Fig. 13 Functional Biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 14 Serum Creatinine market estimates, 2021 - 2033 (USD Million)
Fig. 15 Blood Urea Nitrogen (BUN) market estimates, 2021 - 2033 (USD Million)
Fig. 16 Estimated Glomerular Filtration Rate (eGFR) market estimates, 2021 - 2033 (USD Million)
Fig. 17 Upregulated Proteins market estimates, 2021 - 2033 (USD Million)
Fig. 18 Kidney Injury Molecule-1 (KIM-1) market estimates, 2021 - 2033 (USD Million)
Fig. 19 Neutrophil Gelatinase-Associated Lipocalin (NGAL) market estimates, 2021 - 2033 (USD Million)
Fig. 20 Cystatin C market estimates, 2021 - 2033 (USD Million)
Fig. 21 Interleukin-18 (IL-18) market estimates, 2021 - 2033 (USD Million)
Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
Fig. 23 Other Novel Biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 24 microRNA biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 25 Proteomic/metabolomic markers Middle East renal biomarkers market technology outlook key takeaways
Fig. 26 Middle East renal biomarkers market: diagnostic technique/platform movement analysis
Fig. 27 Immunoassays market estimates, 2021 - 2033 (USD Million)
Fig. 28 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
Fig. 29 ELISA market estimates, 2021 - 2033 (USD Million)
Fig. 30 Clinical chemistry assays market estimates, 2021 - 2033 (USD Million)
Fig. 31 POCT market estimates, 2021 - 2033 (USD Million)
Fig. 32 Middle East renal biomarkers market end use outlook key takeaways
Fig. 33 Middle East renal biomarkers market: end use movement analysis
Fig. 34 Hospitals and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
Fig. 35 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
Fig. 36 Academic & Research Institutes market estimates, 2021 - 2033 (USD Million)
Fig. 37 Pharmaceutical & biotechnology companies market estimates, 2021 - 2033 (USD Million)
Fig. 38 Others market estimates, 2021 - 2033 (USD Million)
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 Renal Biomarkers market: Regional movement analysis
Fig. 41 Saudi Arabia Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 42 UAE Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 43 Kuwait Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 44 Qatar Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 45 Oman Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 46 Strategy framework
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Middle East renal biomarkers market- Key market driver analysis
Fig. 7 Middle East renal biomarkers market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Middle East renal biomarkers market - Porter’s analysis
Fig. 10 Middle East renal biomarkers market - PESTEL analysis
Fig. 11 Middle East renal biomarkers market Biomarkers outlook key takeaways
Fig. 12 Middle East renal biomarkers market: Biomarkers movement analysis
Fig. 13 Functional Biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 14 Serum Creatinine market estimates, 2021 - 2033 (USD Million)
Fig. 15 Blood Urea Nitrogen (BUN) market estimates, 2021 - 2033 (USD Million)
Fig. 16 Estimated Glomerular Filtration Rate (eGFR) market estimates, 2021 - 2033 (USD Million)
Fig. 17 Upregulated Proteins market estimates, 2021 - 2033 (USD Million)
Fig. 18 Kidney Injury Molecule-1 (KIM-1) market estimates, 2021 - 2033 (USD Million)
Fig. 19 Neutrophil Gelatinase-Associated Lipocalin (NGAL) market estimates, 2021 - 2033 (USD Million)
Fig. 20 Cystatin C market estimates, 2021 - 2033 (USD Million)
Fig. 21 Interleukin-18 (IL-18) market estimates, 2021 - 2033 (USD Million)
Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
Fig. 23 Other Novel Biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 24 microRNA biomarkers market estimates, 2021 - 2033 (USD Million)
Fig. 25 Proteomic/metabolomic markers Middle East renal biomarkers market technology outlook key takeaways
Fig. 26 Middle East renal biomarkers market: diagnostic technique/platform movement analysis
Fig. 27 Immunoassays market estimates, 2021 - 2033 (USD Million)
Fig. 28 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
Fig. 29 ELISA market estimates, 2021 - 2033 (USD Million)
Fig. 30 Clinical chemistry assays market estimates, 2021 - 2033 (USD Million)
Fig. 31 POCT market estimates, 2021 - 2033 (USD Million)
Fig. 32 Middle East renal biomarkers market end use outlook key takeaways
Fig. 33 Middle East renal biomarkers market: end use movement analysis
Fig. 34 Hospitals and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
Fig. 35 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
Fig. 36 Academic & Research Institutes market estimates, 2021 - 2033 (USD Million)
Fig. 37 Pharmaceutical & biotechnology companies market estimates, 2021 - 2033 (USD Million)
Fig. 38 Others market estimates, 2021 - 2033 (USD Million)
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 Renal Biomarkers market: Regional movement analysis
Fig. 41 Saudi Arabia Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 42 UAE Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 43 Kuwait Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 44 Qatar Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 45 Oman Middle East renal biomarkers market, 2021 - 2033 (USD Million)
Fig. 46 Strategy framework
